Literature DB >> 26198822

Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab.

Tomohiko Narita1, Naoki Oiso1, Yasunori Taketomo2, Kazunori Okahashi1, Kohei Yamauchi1, Masako Sato1, Shusuke Uchida1, Hiromasa Matsuda1, Akira Kawada1.   

Abstract

Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab-associated adverse events include organ-specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin-dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab-related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease.
© 2015 Japanese Dermatological Association.

Entities:  

Keywords:  Hashimoto disease; insulin-dependent diabetes; malignant melanoma; nivolumab; ultrasonography; vitiligo

Mesh：

Substances：

Year:  2015        PMID： 26198822     DOI： 10.1111/1346-8138.13028

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


  14 in total

Review 1.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

2.  Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Authors:  Priyanka C Iyer; Maria E Cabanillas; Steven G Waguespack; Mimi I Hu; Sonali Thosani; Victor R Lavis; Naifa L Busaidy; Sumit K Subudhi; Adi Diab; Ramona Dadu
Journal:  Thyroid       Date:  2018-10       Impact factor: 6.568

Review 3.  Thyroid dysfunctions secondary to cancer immunotherapy.

Authors:  P Chalan; G Di Dalmazi; F Pani; A De Remigis; A Corsello; P Caturegli
Journal:  J Endocrinol Invest       Date:  2017-12-13       Impact factor: 4.256

4.  PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.

Authors:  Anupam Kotwal; Lisa Kottschade; Mabel Ryder
Journal:  Thyroid       Date:  2020-01-09       Impact factor: 6.568

5.  Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model.

Authors:  Silvia Ippolito; Giulia Di Dalmazi; Fabiana Pani; Elena Sabini; Patrizio Caturegli
Journal:  Thyroid       Date:  2021-12       Impact factor: 6.568

6.  Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung.

Authors:  Isha Verma; Anar Modi; Hemantkumar Tripathi; Abhinav Agrawal
Journal:  BMJ Case Rep       Date:  2016-01-05

7.  Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction.

Authors:  Haruhiko Yamazaki; Hiroyuki Iwasaki; Toshinari Yamashita; Tatsuya Yoshida; Nobuyasu Suganuma; Takashi Yamanaka; Katsuhiko Masudo; Hirotaka Nakayama; Kaori Kohagura; Yasushi Rino; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

8.  Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.

Authors:  Vishal Sehgal; Richard Childress
Journal:  J Transl Int Med       Date:  2017-12-29

Review 9.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 10.  Thyroid disorders induced by checkpoint inhibitors.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Fabio Galetta; Emanuele Citi; Salvatore Benvenga; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.